- freely available
Toxins 2010, 2(5), 978-997; doi:10.3390/toxins2050978
Abstract: The botulinum neurotoxins (BoNT, serotypes A-G) are some of the most toxic proteins known and are the causative agents of botulism. Following exposure, the neurotoxin binds and enters peripheral cholinergic nerve endings and specifically and selectively cleaves one or more SNARE proteins to produce flaccid paralysis. This review centers on the kinetics of the Zn-dependent proteolytic activities of these neurotoxins, and briefly describes inhibitors, activators and factors underlying persistence of toxin action. Some of the structural, enzymatic and inhibitor data that are discussed here are available at the botulinum neurotoxin resource, BotDB (http://botdb.abcc.ncifcrf.gov).
This review focuses on the enzymatic function, thermodynamic properties and susceptibility to inhibitors and activators of the botulinum neurotoxins (BoNTs), the causative agents of botulism. These neurotoxins are metalloproteases (E.C. 22.214.171.124) that belong to the gluzincin clan  and the MA(E) clan/M27 family as classified by the MEROPS database . These multi-domain bacterial proteins are produced by Clostridium botulinum and related species (C. argentinense, baratii, butyricum) and are categorized into seven immunologically distinct serotypes (A-G). In cases of food poisoning, the ingested toxin migrates from the gastrointestinal tract and eventually reaches its primary targets, the peripheral cholinergic nerve terminals to cause flaccid paralysis. The botulinum neurotoxins (BoNTs) are released from the bacteria in complex with various non-toxic proteins that serve to protect the neurotoxin from the degrading proteolytic and low pH environments found in the gastrointestinal tract .
An eighth homologous neurotoxin produced by C. tetani (tetanus neurotoxin, TeNT) causes spastic paralysis (tetanus) and is unaccompanied by accessory proteins . Interestingly, TeNT and BoNT/B share the same molecular target (VAMP) and specifically cleave at the same peptide bond (see Section 2). In contrast to the BoNTs, tetanus neurotoxin (TeNT) enters these same cholinergic termini, is retrogradely transported within motor nerve axons to the spinal cord and is translocated into inhibitory neurons where it produces disinhibition leading to spastic paralysis [4,5]. Thus, the same general mechanism of proteolytic action produces two distinct symptoms that are dependent on their cellular location . Moreover, at concentrations higher than those encountered in vivo, TeNT produces flaccid paralysis in isolated nerve-muscle preparations .
Clinical signs and symptoms of botulism consist of an assortment of abnormalities including those related to the neuromuscular junction and the autonomic nervous systems: dilated pupils, descending symmetric flaccid paralysis, dizziness, blurred vision, dry mouth, sore throat, constipation, nausea, vomiting, abdominal cramps, diarrhea, and paresthesia .
From a basic research perspective, these homologous neurotoxins have been exploited as pharmacologic tools for elucidating the role of the conserved SNAREs that regulate neurally evoked, Ca2+-dependent release of neurotransmitter from synaptic vesicles. In stark contrast to their roles as poisons, the type A and B toxins have been commercially developed as therapeutic agents for a variety of focal dystonias, autonomic dysfunctions, and cosmetic treatments [8,9,10].
These bacterial neurotoxins (molecular weight ~150 kDa) have four domains that comprise their three-dimensional (3D) structures (Figure 1) [11,12,13,14,15]. BoNT/A was the first holotoxin serotype to be resolved crystallographically  (PDB ID: 3BTA). The zinc-dependent proteolytic activities of the light chains (LCs) of BoNT serotypes A, B, and E were first reported in 1992 by Schiavo et al.  and the metalloprotease activity for the structurally homologous TeNT light chain was published during the same year . When expressed, the neurotoxin molecule (progenitor toxin) is a single polypeptide chain. An initial post-translational modification is ‘nicking’, in which several amino acid residues are removed about a third of the way downstream from the N-terminus. This modification results in two chains that are connected by a disulfide bridge.
The N-terminal domain of BoNT, the LC (~50 kDa), is displayed on the right-hand side in Figure 1 and functions as a zinc-dependent protease. The SCOP database  classifies these LCs as a mixture comprised of a-helices + b-strands, remarkably similar to the metalloprotease domain of anthrax lethal factor . The LC is widely accepted to be the toxic moiety of the BoNTs. Although much is known about the role of the BoNT domains, there is no explanation available as to the mechanism involved in the separation of the heavy and light chains that are tightly held together by ionic interactions . Under laboratory conditions this separation of chains typically occurs in a high pH, reducing, high ionic strength environment, i.e., pH 8.4 buffer containing 0.01 M dithiothreitol, 2 M urea, and 0.2 M NaCl . Further studies are required to characterize the mechanism of this separation as it is assumed to occur in living cells.
Surrounding the LC is a relatively unstructured sequence of ~100 amino acids that is part of the N-terminal sequence of the heavy chain (HC). This “belt”, at least in BoNT/A, seems to sterically protect the binding region for the substrate SNAP-25. It has been suggested that the type A belt acts as a chaperone for the translocation of the LC . The belt has also been conjectured to act as a surrogate or a pseudo-substrate . The function of the belt in BoNT/B is less certain because available 3D structures show that it is shifted away from the substrate binding region .
The heavy chain (HC, ~100 kDa) has three structurally dissimilar domains. The so-called C-fragment is composed of two all-b domains (HCC and HCN, ~50 kDa; far left-hand side of Figure 1, red and yellow-orange). Together, the HC domains recognize and bind to nerve terminals in a serotype specific manner using proteins, gangliosides or other macromolecules as receptors . The other domain (HN, ~50 kDa, green) is mainly a-helical (middle portion of Figure 1) and assists in the receptor-mediated internalization and translocation of the toxic moiety . This multistep mechanism of neurotoxin action was first enunciated by Simpson (1980)  and has been kinetically modeled [27,28]. It is worth emphasizing that these neurotoxin molecules are not merely proteases. Rather, they are naturally occurring nano-scale machines  that bind and enter into cholinergic nerve endings to deliver their enzymatic cargos. The BoNTs are highly selective for their substrates, which regulate vesicle-mediated neurotransmission.
2. Proteolytic Activity
The clostridial neurotoxins are noted for their substrate selectivity and cleavage site specificity. Only BoNT/C1 has been shown to attack two different SNARE proteins, syntaxin1 and SNAP-25 (Table 3; [6,29,30,31,32]). Specificity  describes the level of restriction of the cleavage sites at peptide backbone locations in a each substrate. Only TeNT and BoNT/B attack the same substrate (VAMP) at the same peptide bond (Q76-F77, human sequence, UniProtKB accession P63027 ).
The first deduced amino acid sequence of a clostridial neurotoxin was determined for TeNT . From this sequence, TeNT was predicted to be a Zn-dependent protease . This frequently overlooked bioinformatic forecast was based solely on the zincin sequence pattern (HExxH) that is found to be associated with the active-site of the prototypical metalloprotease thermolysin. This prediction was experimentally verified and localized to the LC [18,37,38]. As expected, this protease activity can be blocked by chelators [29,39].
The clostridial neurotoxins belong to the gluzincin subgroup of metalloproteases that has the HExxH…E pattern [1,40]. For the BoNT/A sequence (strain Hall / ATCC 3502 / NCTC 13319; UniProtKB accession BXA1_CLOBH), the invariant histidine and glutamate residues (H223, H227, E262) form non-covalent bonds with the zinc ion and the glutamate (E224) is the active site residue. A more detailed version summarizing a 10-residue consensus pattern of the Zn-binding region is described in the Prosite database  for neutral zinc metallopeptidases.
The variability of LC sequence identity percentages ranges from 31-59% when pair-wise alignments are performed with the seven BoNT serotypes and TeNT  (Table 1). The substrate locations cleaved by the seven BoNT serotypes are summarized in Table 2 . Representations of the 3D structures of the BoNT holotoxin, LC, C-fragment (HCC) and a variety of mutants along with references and other material are located at the BotDB resource (see Table 3).
It should be noted that in rats, VAMP1 unlike VAMP2, is not cleaved by BoNT/B because it has VF instead of QF that is located at this cleavage site in the corresponding mouse or human proteins.
a Abbreviations in the right most column are linked to various sites: J, Jmol graphics program; P, PDB website; Pf, PDB file; D, DSSP Summary; bXm, literature reference from botXminer; Pm, PubMed; Inh, inhibitor.
There is also evidence for the need of relatively long minimal substrates to support cleavage. For example, a 62-mer VAMP fragment for TeNT , and a 17-mer SNAP-25 fragment for BoNT/A  have been documented. The need of relatively long minimal substrates is consistent with the computational results in which the binding free energy in the model became more favorable as the substrate (a VAMP fragment) bound in a zipper-like manner to form a complex with the LC of BoNT/B .
One conclusion from these observations is that there is a requirement for the substrate to bind at sites that are distal to the active site. From analysis of multiple sequence alignments, it was noted that substrate selectivity could be provided “by the critical positioning of the substrate by the non-perfectly conserved residues … plus the residues flanking the active-site region“ . From X-ray crystallographic studies by Brunger’s group, the discontinuous binding locations for SNAP-25 are distal to the catalytic site. The term exosites defined these locations on the BoNT/A-LC  (PDB ID: 1XTG; Table 3). Substrate specificity was described in terms of an array of exosites. An abundance of binding sites is in accord with the enzyme-substrate interface area of 4,840 Å2 for BoNT/A that is about four times larger than the typical protein-protein interface .
The structures of the active sites of three neurotoxins (A, B and E) were considered to be virtually identical. From this analysis it was concluded that substrate recognition does not occur at the catalytic machinery . Furthermore, the data showed that substrate binding induced structural changes that probably influenced catalytic activity and that the rational design of specific inhibitors of BoNT/A could benefit from a knowledge of the exosite structures that recognize the substrate .
3. Enzyme Kinetics
Cell-free assays were initially developed in which the toxin was combined with the appropriate substrate and kinetics of substrate cleavage could be monitored and analyzed [30,41,46,47,48,49]. Initially, samples of holotoxin that were isolated and purified from the organism were used. When recombinant techniques were able to express the LC in E. coli or yeast, this toxin fragment replaced the holotoxins in these assays.
In general, experiments with LC-A and SNAP-25 fragments >61 residues or full length substrates produce a range of kcat/Km values (104 to 106 s-1M-1) that is larger compared to the range determined from experiments with LC-A and the 17-mer SNAP-25 fragment (102 to 103 s-1M-1). Experiments using reduced holotoxin produced a similar quantitative trend, in which the full length substrate was associated with larger values for kcat/Km than those observed using the 17-mer fragment.
As the ratio kcat/Km increases, the enzymatic performance usually increases. The term “performance constant” has been suggested for this ratio and is considered to be a more accurate descriptor than the “specificity constant” . The largest ratio in the data set shown in Figure 1 (filled diamond) is 60 s-1/16.2 mM or 3.7 × 106 s-1M-1 using the LC-A (1-425) and a 61-mer SNAP-25 fragment. This ratio is 2-3 orders of magnitude below the diffusion limit , suggesting that only in a fraction of substrate-enzyme collisions are productive and, therefore, the cleavage reaction appears to be the limiting step.
This toxin-substrate combination may represent an optimal condition for selecting a standard for testing active-site inhibitors in cell-free assays. Taking into consideration that this ratio has not been measured within the intracellular milieu of presynaptic termini (Section 6), it is currently premature to define standards based on the kinetic values obtained in cell-free systems. Rather a set of different cell-free conditions may be necessary to evaluate the effectiveness of candidate inhibitors (Section 4).
To support the idea that the catalytic step is indeed rate limiting, one can calculate the value of the dissociation reaction rate of the toxin-substrate complex and compare it to the value of kcat. Relatively few studies have determined the dissociation constant (Kd) for the SNAP-25 BoNT/A interaction [50,54]. To achieve this experimentally, mutants were developed to produce a non-cleavable substrate and a value of Kd = 2.33 × 10-7 M was determined . This value along with the Km and kcat values of the toxin- cleavable substrate reaction, forward (k1) and backward (k-1) rates for the dissociation reaction can be calculated. Assuming that the following reaction occurs
E + S ⇌ ES g E + P
and that Michaelis-Menten kinetics are obeyed to generate the product (P), the equations for Km
can be solved to yield the on rate
and the off rate
of the substrate (S) with respect to the toxin (E). In the experiments using the wild type LC-A and the recombinant SNAP-25 His6-tagged substrate, where Km = 9.8 × 10-6 M, kcat=1.71 × 101 s-1, and Kd = 2.33 × 10-7 M , the calculated values of k1 and k-1 are 7.7 × 1012 s-1M-1 and 1.8 × 106 s-1, respectively. Using equations 3 and 4, the value of kcat is about 105 times slower that k-1. Using a LC-A concentration of 100 nM results in a forward rate, k1[E] = 7.7 × 105 s-1, which is more than 104-times faster than kcat. Thus, these calculations support the idea that product formation is the rate-limiting step in reaction 1.
In the quest for inhibitors that antagonize the toxic effects produced by the clostridial neurotoxins, well-studied inhibitors of other enzymes, such as thermolysin and angiotensin converting enzyme (ACE), were initially tested. Depending on experimental conditions, the blockade of TeNT activity did not occur with high concentrations of phosphoramidon, thiorphan or trans-epoxysuccinic acid (E64), which inhibits thiol proteases . On the other hand, phosphoramidon, a thermolysin inhibitor, was effective against the TeNT LC  or was a weak inhibitor of VAMP cleavage by BoNT/B . Phosphoramidon moderately prolonged the half- times-to-block produced by BoNT/A or B at the NMJ . Captopril, a potent ACE inhibitor, at a relatively high (1.5 mM) concentration only produced a short delay before complete BoNT-induced paralysis in NMJ preparations [57,58].
Because of the neurobiology associated with these neurotoxins, blocking their effects may involve more than antagonizing their catalytic activity and, consequently, a variety of additional approaches have been attempted. The toxin domains that take part in the multi-step intoxication reactions for BoNT binding, internalization, translocation and toxicity have been targets of a variety of candidate inhibitors. For example, several naturally occurring lectins containing sialic acid were effective (Ki ~ 100 nM) in preventing BoNT/ A, B, C1, D, E, F and TeNT from binding to presynaptic terminals .
Internalization and translocation of the toxic moiety requires acidic vesicular compartments and metabolic energy. Agents that prevent pH drops that accompany vesicle-mediated endocytosis have been examined. Proton ionophores, nigericin and monensin, which are thought to antagonize the translocation of the LC, produced delays in the production of toxicity in NMJ preparations . Other blockers of vesicular acidification, chloroquine, aminoquinolines  and selected quinolines  have also been tested. The onset of paralysis in NMJ experiments caused by BoNT/A, B, and C1 were blocked in a concentration-dependent manner with millimolar amounts of ammonium chloride and methylamine hydrochloride. Internalization was delayed and the toxins were susceptible to extracellular antibodies . Uncouplers of oxidative phosphorylation CCCP, FCCP  and inhibitors of vesicular H+ ATPase  have also been examined. Some of these compounds were toxic and, at best, those that were not toxic had low safety margins that prevented them from being considered as therapeutic candidates. In addition, some candidate compounds may transiently antagonize the effects of some serotypes (e.g., BoNT/A). Selected aminopyridines act indirectly by blocking K+ channels which prolongs action potential durations and increases Ca2+ influx into nerve terminals thereby transiently overcoming the effects of BoNT/A [64,65,66].
With respect to the development of candidate inhibitor compounds, the toxic reaction step involving the proteolysis of one of the SNARE proteins has been the major focus of attention over the past 10 years. A variety of conventional and novel approaches have been used to develop active-site inhibitors and only a few examples will be mentioned here. Extensive in vivo testing has been delayed in favor of screening candidate inhibitors using isolated, mouse phrenic nerve-hemidiaphragm preparations . More recently, studies have sought to understand the properties of the reactants and the minimal requirements for proteolysis in cell-free preparations. As mentioned in Section 2, determinations have been made of which substrate fragments can support cleavage by a neurotoxin [32,43,68,69,70,71]. Some of these studies evolved into searches for peptide inhibitors of this reaction including synthetic peptides with proline-rich motifs . Investigations of peptide inhibitors have inspired the development of substrate-based peptidomimetics as novel active-site inhibitors .
Low molecular weight organic compounds have been synthesized and screened for inhibitory activity. A crystallographic study of BoNT/B in complex with bis(5-amidino-2-benzimidazolyl) methane revealed that this compound had rearranged the active site, and removed the zinc ion that, presumably, caused the loss of proteolytic activity . Vast quantities of products emerging from combinatorial chemical techniques  have been subjected to high throughput screening systems . In contrast, the pharmacophore concept and structure-activity relationships (SAR) for drug discovery have exploited computational chemistry techniques . Computer aided designs have enabled the refinement of a lead compound having an IC50 value of 100 mM to one having a Ki value of 760 nM . A recent inhibitor designed on SAR principles has been co-crystallized with BoNT/A-LC (PDB ID: 3DSE) and has a Ki value of 41 nM . In this case, tight-binding inhibitor kinetics may be more appropriate for analysis than traditional competitive inhibitor models .
Some of these procedures have led to the development of the first irreversible inhibitor based on a benzylidene cyclopentenedione structure whose mechanism involves covalent modification of the active site . Most recently, the identification of exosites  on the LC-A (Section 2) has led to the development of non-competitive blockers of substrate binding at these sites as exemplified by the natural product d-chicoric acid (I1) from Echinacea . It will be important to determine how toxic these compounds are in cultured cells and in animal models. From a toxicity perspective, it will be important to understand the findings of Janda’s group , in which the two most efficacious compounds in vivo showed less activity in cellular assays. Indeed, one of these compounds was cytotoxic at concentrations three orders of magnitude below its effective dose in vivo.
Within the BotDB resource, the BotDBI section has information on more than 60 inhibitor candidates including peptides, synthetic and natural compounds, and monoclonal antibodies, along with references. Searches for candidate inhibitors can be done by author name, value of IC50, inhibitor site, inhibitor type, value of Ki, inhibitor name PubMedID BoNT serotype, and inhibitor structure. An example of a list of synthetic compounds in the BotDBI section is shown in Figure 3.
In another part of the BotDB resource is an on-line, user friendly tool that converts IC50 to Ki values depending on whether the inhibitory mechanism is competitive, uncompetitive, or noncompetitive (Figure 4) . The upper portion of this output lists the parameter values (in mM units) that need to be entered by the end user, i.e., enzyme (toxin) concentration, substrate concentration, Km and IC50. The middle panels display the results from the Ki calculations assuming that three different mechanisms follow either the classic (Michaelis-Menten) scheme or are associated with a tightly bound inhibitor. The bottom panel has color-coded histograms for classic (red bars) and for tightly bound (blue bar) inhibitors from six different calculations for the Ki values. This display allows the user to visualize and readily compare the results.
Schmidt and Bostian  described the stimulating effects of bovine serum albumen (BSA) and other serum albumins that were kinetically analyzed by following the BoNT/A-mediated cleavage of the 17-mer SNAP-25 fragment by BoNT/A. Addition of 1 mg/ml BSA, produced a 10-fold increase in the value of kcat and a three-fold decrease in Km leading to an increase of 30-fold for the performance constant (kcat/Km, Section 3). This enhancing effect of BSA has been noted with other enzymes .
Beyond an apparent non-specific stabilizing effect that may underlie the action of BSA, some low-molecular weight synthetic ligands having a 2-acylguanidyl-5-phenyl thiophene scaffold have been reported to activate the enzymatic effects of BoNT/A under cell-free conditions . In that study, the value of Km was reduced by the ligands while the value of kcat was essentially unaffected. Importantly, this activation was determined not to be a detergent-like effect. The results were so striking that these authors described their compounds as being super-activators.
One implication of these findings may affect the use of these toxins as pharmaceutical treatments for a variety of conditions and disorders. A better therapeutic strategy may be created if these activating compounds were part of the toxin formulation. Ideally, less toxin would be needed to produce an optimal level of therapeutic benefit, thus reducing the incidence of toxic side effects and causing or development of resistance to treatment.
At higher concentrations, some ligands may exhibit both stimulatory and inhibitory effects. The theoretical basis for this dual mechanism for a single ligand have been kinetically analyzed in detail by others, e.g., [86,87]. Such a concentration-dependence is predicted to be observed in cell-free systems using a wider range of inhibitor and substrate concentrations than have thus far been examined.
6. Future Research
The long-lasting effects of botulism are well known [12,14,88] with patients still presenting some of the toxic signs and symptoms a year after onset. In one extreme case, the effects due to type A toxin poisoning persisted for over five years . It is clinically relevant to understand the underlying mechanism of persistence. As mentioned in Section 5, the presence of an additive that prolongs the persistence of BoNT-induced effects could be exploited by caregivers to provide longer lasting therapeutic effects with a reduced number of injection sessions along with fewer and less severe adverse reactions for the patient.
Two hypotheses have been advanced. The long lasting activity of the type A toxin was hypothesized to be based on the longevity of the LC within the nerve terminal [90,91] or to a slower turnover of the truncated SNAP-25 generated by BoNT/A-mediated proteolysis. Presently, there is no direct evidence for either the BoNT LC or for the SNAP-25 cleavage products to have a long half life. Moreover, the proposed long-lived activity of the BoNT/A LC is apparently not due to an extraordinary thermostability compared to that of thermolysin. This is because the estimated activation energy for unfolding, Ea, is ~ 9 kJ/mol for the reduced form and 22 kJ/mol for the unreduced form of BoNT . These values are low in comparison with the Ea for inactivation of the more temperature stable thermolysin which is ~149 kJ/mol .
Dolly and colleagues challenged the view that BoNT/A activity was extraordinarily stable. These researchers hypothesized that the protracted time course of the toxic effects was due to the truncated SNAP-25 that results from BoNT/A-mediated cleavage of the last nine C-terminal residues [94,95,96]. Evidence was presented in which one of the cleavage fragments formed a long-lasting but incompetent SNARE complex with syntaxin and VAMP. Normally the SNARE complex dissociates into the three monomers in conjunction with a-SNAP [a-soluble N-ethylmaleimide-sensitive fusion protein (NSF) attachment protein] and NSF [97,98].
An issue that may be related to the persistence phenomenon is the differential localization of the LCs for BoNT/A and E. A di-leucine motif is present in the LC of BoNT/A, but does not exist in the LC of BoNT/E. It is believed that this motif functions as a sorting signal to keep the LC-A associated with the cytoplasmic surface of the nerve terminal, while the LC-E is removed from this site and presumably metabolized into an inactive form .
Focusing on the LC stability portion of this hypothesis, mechanisms unique to the intracellular environment may lead to persistence of LC-A within nerve terminals that may not occur in cell-free systems. For example, persistence of proteolytic activity could be due to post-translational modifications (PTMs) of LC-A or as a consequence of interactions of LC-A with molecules that serve as molecular chaperones. Like other enzymes, BoNT is regulated through post-translational modifications such as the nicking process that creates the LC and HC (Section 1) along with the reduction of the interchain disulfide bond that is essential to the activation of BoNT or TeNT [29,38]. What is not known to any great extent are other possible covalent modifications in which low molecular weight groups are added. The existence of phosphorylation of tyrosines of the type A, B, E and TeNT LCs , which may enhance its thermal stability while retaining its catalytic properties has been reported but is of uncertain functional significance within neurons . Within the environment of the nerve terminal, rate constants (Section 3) may be affected by molecular crowding or confinement . Protein structural stability and enzymatic efficiency could be enhanced by endogenous substances that are usurped by the toxin to act as molecular chaperones. Such concepts provide a physical basis for long-lived enzyme activity when considering persistence of BoNT/A and perhaps other serotypes.
Because the persistence hypotheses considered above are not mutually exclusive, both could be merged into a single framework to account for long-term paralysis. Future research is required to advance our understanding of this intriguing phenomenon and the related problem of developing activator additives to improve the BoNT therapeutic effects of the BoNTs. In addition, continued improvements are needed in developing inhibitors to ameliorate BoNT toxicity. These would be used for treatment of overdose following clinical use, for treatment of accidental intoxication in the human and animal populations and most importantly for treatment of casualties after a bioterrorist attack.
This study was supported by the Defense Threat Reduction Agency, Joint Science and Technology Office-Chemical Biological Defense project 3.10043-07-RD-B (FJL), and project T.T.0011-06-RC_B (MA) and by the National Cancer Institute, National Institutes of Health under contract HHSN261200800001E. Opinions, interpretations, conclusions, and recommendations are those of the authors and are not necessarily endorsed by the U.S. Army or the Department of Health and Human Services. The mention of trade names, commercial products, or organizations does not imply endorsement by the U.S. Government. Electronic versions for some of the citations used in the analysis for this paper were obtained at the National Library of Medicine, the Uniform Services University of the Health Sciences and the Sheridan Libraries at Johns Hopkins University.
- Gomis-Ruth, F.X. Structural aspects of the metzincin clan of metalloendopeptidases. Mol. Biotechnol. 2003, 24, 157–202. [Google Scholar] [CrossRef]
- Rawlings, N.D.; Barrett, A.J.; Bateman, A. MEROPS: the peptidase database. Nucleic Acids Res. 2009, 38, D227–D233. [Google Scholar]
- Singh, B.R.; Li, B.; Read, D. Botulinum versus tetanus neurotoxins: why is botulinum neurotoxin but not tetanus neurotoxin a food poison? Toxicon 1995, 33, 1541–1547. [Google Scholar] [CrossRef] [PubMed]
- Rabasseda, X.; Blasi, J.; Marsal, J.; Dunant, Y.; Casanova, A.; Bizzini, B. Tetanus and botulinum toxins block the release of acetylcholine from slices of rat striatum and from the isolated electric organ of Torpedo at different concentrations. Toxicon 1988, 26, 329–336. [Google Scholar]
- Habermann, E.; Dreyer, F.; Bigalke, H. Tetanus toxin blocks the neuromuscular transmission in vitro like botulinum A toxin. Naunyn Schmiedebergs Arch. Pharmacol. 1980, 311, 33–40. [Google Scholar] [CrossRef]
- Washbourne, P.; Pellizzari, R.; Rossetto, O.; Bortoletto, N.; Tugnoli, V.; De Grandis, D.; Eleopra, R.; Montecucco, C. On the action of botulinum neurotoxins A and E at cholinergic terminals. J. Physiol. Paris 1998, 92, 135–139. [Google Scholar] [CrossRef]
- Arnon, S.S.; Schechter, R.; Inglesby, T.V.; Henderson, D.A.; Bartlett, J.G.; Ascher, M.S.; Eitzen, E.; Fine, A.D.; Hauer, J.; Layton, M.; Lillibridge, S.; Osterholm, M.T.; O'Toole, T.; Parker, G.; Perl, T.M.; Russell, P.K.; Swerdlow, D.L.; Tonat, K. Botulinum toxin as a biological weapon: medical and public health management. J. Amer. Med. Assoc. 2001, 285, 1059–1070. [Google Scholar]
- Mejia, N.I.; Vuong, K.D.; Jankovic, J. Long-term botulinum toxin efficacy, safety, and immunogenicity. Mov. Disord. 2005, 20, 592–597. [Google Scholar] [CrossRef] [PubMed]
- Sheffield, J.K.; Jankovic, J. Botulinum toxin in the treatment of tremors, dystonias, sialorrhea and other symptoms associated with Parkinson's disease. Expert Rev. Neurother. 2007, 7, 637–647. [Google Scholar] [CrossRef] [PubMed]
- Lebeda, F.J.; Cer, R.Z.; Stephens, R.; Mudunuri, U. Temporal characteristics of botulinum neurotoxin therapy. Expert Rev. Neurother. 2010, 10, 93–103. [Google Scholar]
- Montal, M. Botulinum Neurotoxin: A Marvel of Protein Design. Annu. Rev. Biochem. 2010, 79. [Epub ahead of print]. [Google Scholar]
- Schiavo, G.; Matteoli, M.; Montecucco, C. Neurotoxins affecting neuroexocytosis. Physiol. Rev. 2000, 80, 717–766. [Google Scholar]
- Montecucco, C.; Schiavo, G. Structure and function of tetanus and botulinum neurotoxins. Q. Rev. Biophys. 1995, 28, 423–472. [Google Scholar] [CrossRef]
- Simpson, L.L. Identification of the major steps in botulinum toxin action. Annu. Rev. Pharmacol. Toxicol. 2004, 44, 167–193. [Google Scholar]
- Sharma, S.K.; Basavanna, U.; Shukla, H.D. Protein domain analysis of C. botulinum type A neurotoxin and its relationship with other botulinum serotypes. Toxins 2010, 2, 1–9. [Google Scholar]
- Swaminathan, S.; Eswaramoorthy, S. Structural analysis of the catalytic and binding sites of Clostridium botulinum neurotoxin B. Nat. Struct. Biol. 2000, 7, 693–699. [Google Scholar] [CrossRef]
- Lacy, D.B.; Tepp, W.; Cohen, A.C.; DasGupta, B.R.; Stevens, R.C. Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat. Struct. Biol. 1998, 5, 898–902. [Google Scholar]
- Schiavo, G.; Rossetto, O.; Santucci, A.; DasGupta, B.R.; Montecucco, C. Botulinum neurotoxins are zinc proteins. J. Biol. Chem. 1992, 267, 23479–23483. [Google Scholar]
- Schiavo, G.; Poulain, B.; Rossetto, O.; Benfenati, F.; Tauc, L.; Montecucco, C. Tetanus toxin is a zinc protein and its inhibition of neurotransmitter release and protease activity depend on zinc. EMBO J. 1992, 11, 3577–3583. [Google Scholar]
- Sigrist, C.J.; Cerutti, L.; de Castro, E.; Langendijk-Genevaux, P.S.; Bulliard, V.; Bairoch, A.; Hulo, N. PROSITE, a protein domain database for functional characterization and annotation. Nucleic Acids Res. 2009, 38, D161–D166. [Google Scholar]
- Tonello, F.; Montecucco, C. The anthrax lethal factor and its MAPK kinase-specific metalloprotease activity. Mol. Aspects Med. 2009, 30, 431–438. [Google Scholar] [CrossRef]
- Sathyamoorthy, V.; DasGupta, B.R. Separation, purification, partial characterization and comparison of the heavy and light chains of botulinum neurotoxin types A, B, and E. J. Biol. Chem. 1985, 260, 10461–10466. [Google Scholar] [PubMed]
- Lomneth, R.; Gimenez, J.; Martin, T.F.; DasGupta, B.R. Calcium-dependent release of norepinephrine from permeabilized PC12 cells is inhibited by approximately 48 and approximately 112 kDa fragments of botulinum neurotoxin type E. Neuropharmacology 1993, 32, 285–259. [Google Scholar] [CrossRef]
- Brunger, A.T.; Breidenbach, M.A.; Jin, R.; Fischer, A.; Santos, J.S.; Montal, M. Botulinum neurotoxin heavy chain belt as an intramolecular chaperone for the light chain. PLoS Pathog. 2007, 3, 1191–1194. [Google Scholar]
- Rossetto, O.; Montecucco, C. Peculiar binding of botulinum neurotoxins. ACS Chem. Biol. 2007, 2, 96–98. [Google Scholar] [CrossRef]
- Lebeda, F.J.; Singh, B.R. Membrane channel activity and translocation of tetanus and botulinum neurotoxins. J. Toxicol.-Toxin Rev. 1999, 18, 45–76. [Google Scholar]
- Simpson, L.L. Kinetic studies on the interaction between botulinum toxin type A and the cholinergic neuromuscular junction. J. Pharmacol. Exp. Ther. 1980, 212, 16–21. [Google Scholar]
- Lebeda, F.J.; Adler, M.; Erickson, K.; Chushak, Y. Onset dynamics of type A botulinum neurotoxin-induced paralysis. J. Pharmacokinet. Pharmacodyn. 2008, 35, 251–267. [Google Scholar] [CrossRef]
- Foran, P.; Shone, C.C.; Dolly, J.O. Differences in the protease activities of tetanus and botulinum B toxins revealed by the cleavage of vesicle-associated membrane protein and various sized fragments. Biochemistry 1994, 33, 15365–15374. [Google Scholar]
- Osen-Sand, A.; Staple, J.K.; Naldi, E.; Schiavo, G.; Rossetto, O.; Petitpierre, S.; Malgaroli, A.; Montecucco, C.; Catsicas, S. Common and distinct fusion proteins in axonal growth and transmitter release. J. Comp. Neurol. 1996, 367, 222–234. [Google Scholar] [CrossRef]
- Williamson, L.C.; Halpern, J.L.; Montecucco, C.; Brown, J.E.; Neale, E.A. Clostridial neurotoxins and substrate proteolysis in intact neurons: botulinum neurotoxin C acts on synaptosomal-associated protein of 25 kDa. J. Biol. Chem. 1996, 271, 7694–7699. [Google Scholar]
- Foran, P.; Lawrence, G.W.; Shone, C.C.; Foster, K.A.; Dolly, J.O. Botulinum neurotoxin C1 cleaves both syntaxin and SNAP-25 in intact and permeabilized chromaffin cells: correlation with its blockade of catecholamine release. Biochemistry 1996, 35, 2630–2636. [Google Scholar]
- Koshland, D.E. Application of a Theory of Enzyme Specificity to Protein Synthesis. Proc. Natl. Acad. Sci. USA 1958, 44, 98–104. [Google Scholar] [CrossRef]
- Gaudet, P.; Lane, L.; Fey, P.; Bridge, A.; Poux, S.; Auchincloss, A.; Axelsen, K.; Braconi Quintaje, S.; Boutet, E.; Brown, P.; Coudert, E.; Datta, R.S.; de Lima, W.C.; de Oliveira Lima, T.; Duvaud, S.; Farriol-Mathis, N.; Ferro Rojas, S.; Feuermann, M.; Gateau, A.; Hinz, U.; Hulo, C.; James, J.; Jimenez, S.; Jungo, F.; Keller, G.; Lemercier, P.; Lieberherr, D.; Moinat, M.; Nikolskaya, A.; Pedruzzi, I.; Rivoire, C.; Roechert, B.; Schneider, M.; Stanley, E.; Tognolli, M.; Sjolander, K.; Bougueleret, L.; Chisholm, R.L.; Bairoch, A. Collaborative annotation of genes and proteins between UniProtKB/Swiss-Prot and dictyBase. Database (Oxford) 2009, 2009, ap016. [Google Scholar] [PubMed]
- Fairweather, N.F.; Lyness, V.A. The complete nucleotide sequence of tetanus toxin. Nucleic Acids Res. 1986, 14, 7809–7812. [Google Scholar]
- Jongeneel, C.V.; Bouvier, J.; Bairoch, A. A unique signature identifies a family of zinc-dependent metallopeptidases. FEBS Lett. 1989, 242, 211–214. [Google Scholar]
- Schiavo, G.; Poulain, B.; Rossetto, O.; Benfenati, F.; Tauc, L.; Montecucco, C. Tetanus toxin is a zinc protein and its inhibition of neurotransmitter release and protease activity depend on zinc. EMBO J. 1992, 11, 3577–3583. [Google Scholar]
- Schiavo, G.; Benfenati, F.; Poulain, B.; Rossetto, O.; Polverino de Laureto, P.; DasGupta, B.R.; Montecucco, C. Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature 1992, 359, 832–835. [Google Scholar]
- Adler, M.; Dinterman, R.E.; Wannemacher, R.W. Protection by the heavy metal chelator N,N,N',N'-tetrakis (2-pyridylmethyl)ethylenediamine (TPEN) against the lethal action of botulinum neurotoxin A and B. Toxicon 1997, 35, 1089–1100. [Google Scholar] [CrossRef]
- Hooper, N.M. Families of zinc metalloproteases. FEBS Lett. 1994, 354, 1–6. [Google Scholar]
- Lebeda, F.J.; Olson, M.A. Predictions of secondary structure and solvent accessibility of the light chain of the clostridial neurotoxins. J. Nat. Toxins 1998, 7, 227–238. [Google Scholar]
- Li, Y.; Foran, P.; Fairweather, N.F.; de Paiva, A.; Weller, U.; Dougan, G.; Dolly, J.O. A single mutation in the recombinant light chain of tetanus toxin abolishes its proteolytic activity and removes the toxicity seen after reconstitution with native heavy chain. Biochemistry 1994, 33, 7014–7020. [Google Scholar]
- Schmidt, J.J.; Bostian, K.A. Proteolysis of synthetic peptides by type A botulinum neurotoxin. J. Protein Chem. 1995, 14, 703–708. [Google Scholar] [CrossRef]
- Olson, M.A.; Armendinger, T.L. Free-energy contributions to complex formation between botulinum neurotoxin type B and synaptobrevin fragment. Protein Eng. 2002, 15, 739–743. [Google Scholar] [CrossRef]
- Lebeda, F.J.; Olson, M.A. Secondary structural predictions for the clostridial neurotoxins. Proteins 1994, 20, 293–300. [Google Scholar] [CrossRef]
- Breidenbach, M.A.; Brunger, A.T. Substrate recognition strategy for botulinum neurotoxin serotype A. Nature 2004, 432, 925–929. [Google Scholar] [CrossRef]
- Pang, Y.P.; Vummenthala, A.; Mishra, R.K.; Park, J.G.; Wang, S.; Davis, J.; Millard, C.B.; Schmidt, J.J. Potent new small-molecule inhibitor of botulinum neurotoxin serotype A endopeptidase developed by synthesis-based computer-aided molecular design. PLoS One 2009, 4, e7730. [Google Scholar]
- Sukonpan, C.; Oost, T.; Goodnough, M.; Tepp, W.; Johnson, E.A.; Rich, D.H. Synthesis of substrates and inhibitors of botulinum neurotoxin type A metalloprotease. J. Pept. Res. 2004, 63, 181–193. [Google Scholar]
- Binz, T.; Blasi, J.; Yamasaki, S.; Baumeister, A.; Link, E.; Sudhof, T.C.; Jahn, R.; Niemann, H. Proteolysis of SNAP-25 by types E and A botulinal neurotoxins. J. Biol.Chem. 1994, 269, 1617–1620. [Google Scholar]
- Binz, T.; Bade, S.; Rummel, A.; Kollewe, A.; Alves, J. Arg(362) and Tyr(365) of the botulinum neurotoxin type a light chain are involved in transition state stabilization. Biochemistry 2002, 41, 1717–1723. [Google Scholar]
- Koshland, D.E. The Application and Usefulness of the Ratio kcat/KM. Bioorg. Chem. 2002, 30, 211–213. [Google Scholar] [CrossRef]
- Fu, Z.; Chen, S.; Baldwin, M.R.; Boldt, G.E.; Crawford, A.; Janda, K.D.; Barbieri, J.T.; Kim, J.J. Light chain of botulinum neurotoxin serotype A: structural resolution of a catalytic intermediate. Biochemistry 2006, 45, 8903–8911. [Google Scholar]
- Fersht, A. Structure and Mechanism in Protein Science; W.H. Freeman and Company: New York, NY, USA, 1999. [Google Scholar]
- Vaidyanathan, V.V.; Yoshino, K.; Jahnz, M.; Dorries, C.; Bade, S.; Nauenburg, S.; Niemann, H.; Binz, T. Proteolysis of SNAP-25 isoforms by botulinum neurotoxin types A, C, and E: domains and amino acid residues controlling the formation of enzyme-substrate complexes and cleavage. J. Neurochem. 1999, 72, 327–337. [Google Scholar] [PubMed]
- Sanders, D.; Habermann, E. Evidence for a link between specific proteolysis and inhibition of [3H]-noradrenaline release by the light chain of tetanus toxin. Naunyn Schmiedebergs Arch. Pharmacol. 1992, 346, 358–361. [Google Scholar]
- Adler, M.; Nicholson, J.D.; Starks, D.F.; Kane, C.T.; Cornille, F.; Hackley, B.E., Jr. Evaluation of phosphoramidon and three synthetic phosphonates for inhibition of botulinum neurotoxin B catalytic activity. J. Appl. Toxicol. 1999, 19 (Suppl. 1), S5–S11. [Google Scholar] [CrossRef] [PubMed]
- Deshpande, S.S.; Sheridan, R.E.; Adler, M. A study of zinc-dependent metalloendopeptidase inhibitors as pharmacological antagonists in botulinum neurotoxin poisoning. Toxicon 1995, 33, 551–557. [Google Scholar] [CrossRef]
- Adler, M.; Deshpande, S.S.; Sheridan, R.E.; Lebeda, F.J. Evaluation of captopril and other potentially therapeutic compounds in antagonizing botulinum toxin-induced muscle paralysis. In Therapy with Botulinum Toxin; Jankovic, J., Hallett, M., Eds.; Marcel Dekker, Inc.: New York, NY, USA, 1994; pp. 63–70. [Google Scholar]
- Bakry, N.; Kamata, Y.; Simpson, L.L. Lectins from Triticum vulgaris and Limax flavus are universal antagonists of botulinum neurotoxin and tetanus toxin. J. Pharmacol. Exp. Ther. 1991, 258, 830–836. [Google Scholar]
- Simpson, L.L. The interaction between aminoquinolines and presynaptically acting neurotoxins. J. Pharmacol. Exp. Ther. 1982, 222, 43–48. [Google Scholar]
- Deshpande, S.S.; Sheridan, R.E.; Adler, M. Efficacy of certain quinolines as pharmacological antagonists in botulinum neurotoxin poisoning. Toxicon 1997, 35, 433–445. [Google Scholar] [CrossRef]
- Simpson, L.L. Ammonium chloride and methylamine hydrochloride antagonize clostridial neurotoxins. J. Pharmacol. Exp. Ther. 1983, 225, 546–552. [Google Scholar]
- Simpson, L.L.; Coffield, J.A.; Bakry, N. Inhibition of vacuolar adenosine triphosphatase antagonizes the effects of clostridial neurotoxins but not phospholipase A2 neurotoxins. J. Pharmacol. Exp. Ther. 1994, 269, 256–262. [Google Scholar]
- Simpson, L.L. A preclinical evaluation of aminopyridines as putative therapeutic agents in the treatment of botulism. Infect. Immun. 1986, 52, 858–862. [Google Scholar]
- Simpson, L.L. Use of pharmacologic antagonists to deduce commonalities of biologic activity among clostridial neurotoxins. J. Pharmacol. Exp. Ther. 1988, 245, 867–872. [Google Scholar]
- Adler, M.; Scovill, J.; Parker, G.; Lebeda, F.J.; Piotrowski, J.; Deshpande, S.S. Antagonism of botulinum toxin-induced muscle weakness by 3,4-diaminopyridine in rat phrenic nerve-hemidiaphragm preparations. Toxicon 1995, 33, 527–537. [Google Scholar]
- Simpson, L.L. Pharmacological studies on the subcellular site of action of botulinum toxin type A. J. Pharmacol. Exp. Ther. 1978, 206, 661–669. [Google Scholar]
- Shone, C.C.; Quinn, C.P.; Wait, R.; Hallis, B.; Fooks, S.G.; Hambleton, P. Proteolytic cleavage of synthetic fragments of vesicle-associated membrane protein, isoform-2 by botulinum type B neurotoxin. Eur. J. Biochem. 1993, 217, 965–971. [Google Scholar] [CrossRef]
- Yamasaki, S.; Baumeister, A.; Binz, T.; Blasi, J.; Link, E.; Cornille, F.; Roques, B.; Fykse, E.M.; Sudhof, T.C.; Jahn, R.; et al. Cleavage of members of the synaptobrevin/VAMP family by types D and F botulinal neurotoxins and tetanus toxin. J. Biol. Chem. 1994, 269, 12764–12772. [Google Scholar] [PubMed]
- Cornille, F.; Goudreau, N.; Ficheux, D.; Niemann, H.; Roques, B.P. Solid-phase synthesis, conformational analysis and in vitro cleavage of synthetic human synaptobrevin II 1-93 by tetanus toxin L chain. Eur. J. Biochem. 1994, 222, 173–181. [Google Scholar] [CrossRef]
- Shone, C.C.; Roberts, A.K. Peptide substrate specificity and properties of the zinc-endopeptidase activity of botulinum type B neurotoxin. Eur. J. Biochem. 1994, 225, 263–270. [Google Scholar] [CrossRef]
- Cornille, F.; Deloye, F.; Fournie-Zaluski, M.C.; Roques, B.P.; Poulain, B. Inhibition of neurotransmitter release by synthetic proline-rich peptides shows that the N-terminal domain of vesicle-associated membrane protein/synaptobrevin is critical for neuro-exocytosis. J. Biol. Chem. 1995, 270, 16826–16832. [Google Scholar]
- Zuniga, J.E.; Schmidt, J.J.; Fenn, T.; Burnett, J.C.; Arac, D.; Gussio, R.; Stafford, R.G.; Badie, S.S.; Bavari, S.; Brunger, A.T. A potent peptidomimetic inhibitor of botulinum neurotoxin serotype A has a very different conformation than SNAP-25 substrate. Structure 2008, 16, 1588–1597. [Google Scholar]
- Eswaramoorthy, S.; Kumaran, D.; Swaminathan, S. A novel mechanism for Clostridium botulinum neurotoxin inhibition. Biochemistry 2002, 41, 9795–9802. [Google Scholar] [CrossRef]
- Martin, L.; Cornille, F.; Turcaud, S.; Meudal, H.; Roques, B.P.; Fournie-Zaluski, M.C. Metallopeptidase inhibitors of tetanus toxin: A combinatorial approach. J. Med. Chem. 1999, 42, 515–525. [Google Scholar]
- Boldt, G.E.; Eubanks, L.M.; Janda, K.D. Identification of a botulinum neurotoxin A protease inhibitor displaying efficacy in a cellular model. Chem. Commun. (camb) 2006, 3063–3065. [Google Scholar] [PubMed]
- Burnett, J.C.; Opsenica, D.; Sriraghavan, K.; Panchal, R.G.; Ruthel, G.; Hermone, A.R.; Nguyen, T.L.; Kenny, T.A.; Lane, D.J.; McGrath, C.F.; Schmidt, J.J.; Vennerstrom, J.L.; Gussio, R.; Solaja, B.A.; Bavari, S. A refined pharmacophore identifies potent 4-amino-7-chloroquinoline-based inhibitors of the botulinum neurotoxin serotype A metalloprotease. J. Med. Chem. 2007, 50, 2127–2136. [Google Scholar]
- Zuniga, J.E.; Schmidt, J.J.; Fenn, T.; Burnett, J.C.; Arac, D.; Gussio, R.; Stafford, R.G.; Badie, S.S.; Bavari, S.; Brunger, A.T. A potent peptidomimetic inhibitor of botulinum neurotoxin serotype A has a very different conformation than SNAP-25 substrate. Structure 2008, 16, 1588–1597. [Google Scholar] [CrossRef]
- Cer, R.Z.; Mudunuri, U.; Stephens, R.; Lebeda, F.J. IC50-to-Ki: a web-based tool for converting IC50 to Ki values for inhibitors of enzyme activity and ligand binding. Nucleic Acids Res. 2009, 37, W441–W445. [Google Scholar]
- Capkova, K.; Hixon, M.S.; Pellett, S.; Barbieri, J.T.; Johnson, E.A.; Janda, K.D. Benzylidene cyclopentenediones: First irreversible inhibitors against botulinum neurotoxin A's zinc endopeptidase. Bioorg. Med. Chem. Lett. 2010, 20, 206–208. [Google Scholar]
- Silhar, P.; Capkova, K.; Salzameda, N.T.; Barbieri, J.T.; Hixon, M.S.; Janda, K.D. Botulinum neurotoxin A protease: discovery of natural product exosite inhibitors. J. Am. Chem. Soc. 2010, 132, 2868–2869. [Google Scholar]
- Eubanks, L.M.; Hixon, M.S.; Jin, W.; Hong, S.; Clancy, C.M.; Tepp, W.H.; Baldwin, M.R.; Malizio, C.J.; Goodnough, M.C.; Barbieri, J.T.; Johnson, E.A.; Boger, D.L.; Dickerson, T.J.; Janda, K.D. An in vitro and in vivo disconnect uncovered through high-throughput identification of botulinum neurotoxin A antagonists. Proc. Natl. Acad. Sci. USA 2007, 104, 2602–2607. [Google Scholar]
- Schmidt, J.J.; Bostian, K.A. Endoproteinase activity of type A botulinum neurotoxin: substrate requirements and activation by serum albumin. J. Protein Chem. 1997, 16, 19–26. [Google Scholar] [CrossRef]
- Costa, S.A.; Tzanov, T.; Ana Filipa Carneiro, A.F.; Paar, A.; Gubitz, G.M.; Cavaco-Paulo, A. Studies of stabilization of native catalase using additives. Enz. Microb. Technol. 2002, 30, 387–391. [Google Scholar] [CrossRef]
- McAllister, L.A.; Hixon, M.S.; Kennedy, J.P.; Dickerson, T.J.; Janda, K.D. Superactivation of the Botulinum Neurotoxin Serotype A Light Chain Metalloprotease: A New Wrinkle in Botulinum Neurotoxin. J. Am. Chem. Soc. 2006, 128, 4176–4177. [Google Scholar]
- Botts, J.; Morales, M. Analytical description of the effects of modifiers and of enzyme multivalency upon the steady state catalyzed reaction rate. Trans. Faraday Soc. 1953, 49, 696–707. [Google Scholar]
- Cornish-Bowden, A. Fundamentals of Enzyme Kinetics; Butterworths: London, UK, 1979. [Google Scholar]
- Verderio, C.; Rossetto, O.; Grumelli, C.; Frassoni, C.; Montecucco, C.; Matteoli, M. Entering neurons: botulinum toxins and synaptic vesicle recycling. EMBO Rep. 2006, 7, 995–999. [Google Scholar] [CrossRef]
- Marcus, S.M. Reflections on the care of a patient severely poisoned by 'rogue' botulinum toxin and rendered paralysed for a protracted hospital stay. Botulinum J. 2009, 1, 318–339. [Google Scholar]
- Adler, M.; Keller, J.E.; Sheridan, R.E.; Deshpande, S.S. Persistence of botulinum neurotoxin A demonstrated by sequential administration of serotypes A and E in rat EDL muscle. Toxicon 2001, 39, 233–243. [Google Scholar]
- Keller, J.E.; Neale, E.A.; Oyler, G.; Adler, M. Persistence of botulinum neurotoxin action in cultured spinal cord cells. FEBS Lett. 1999, 456, 137–142. [Google Scholar] [CrossRef]
- Cai, S.; Sarkar, H.K.; Singh, B.R. Enhancement of the endopeptidase activity of botulinum neurotoxin by its associated proteins and dithiothreitol. Biochemistry 1999, 38, 6903–6910. [Google Scholar]
- Takita, T.; Aono, T.; Sakurama, H.; Itoh, T.; Wada, T.; Minoda, M.; Yasukawa, K.; Inouye, K. Effects of introducing negative charges into the molecular surface of thermolysin by site-directed mutagenesis on its activity and stability. Biochim. Biophys. Acta 2008, 1784, 481–488. [Google Scholar]
- Schulte-Baukloh, H.; Zurawski, T.H.; Knispel, H.H.; Miller, K.; Haferkamp, A.; Dolly, J.O. Persistence of the synaptosomal-associated protein-25 cleavage product after intradetrusor botulinum toxin A injections in patients with myelomeningocele showing an inadequate response to treatment. BJU Int. 2007, 100, 1075–1080. [Google Scholar]
- Meunier, F.A.; Lisk, G.; Sesardic, D.; Dolly, J.O. Dynamics of motor nerve terminal remodeling unveiled using SNARE-cleaving botulinum toxins: the extent and duration are dictated by the sites of SNAP-25 truncation. Mol. Cell. Neurosci. 2003, 22, 454–466. [Google Scholar]
- O'Sullivan, G.A.; Mohammed, N.; Foran, P.G.; Lawrence, G.W.; Dolly, J.O. Rescue of exocytosis in botulinum toxin A-poisoned chromaffin cells by expression of cleavage-resistant SNAP-25. Identification of the minimal essential C-terminal residues. J. Biol. Chem. 1999, 274, 36897–36904. [Google Scholar] [PubMed]
- Hayashi, T.; Yamasaki, S.; Nauenburg, S.; Binz, T.; Niemann, H. Disassembly of the reconstituted synaptic vesicle membrane fusion complex in vitro. EMBO J. 1995, 14, 2317–2325. [Google Scholar]
- Poulain, B.; Popoff, M.R.; Molgó, J. How do the Botulinum Neurotoxins block neurotransmitter release: from botulism to the molecular mechanism of action. Botulinum J. 2008, 1, 14–87. [Google Scholar] [CrossRef]
- Fernandez-Salas, E.; Steward, L.E.; Ho, H.; Garay, P.E.; Sun, S.W.; Gilmore, M.A.; Ordas, J.V.; Wang, J.; Francis, J.; Aoki, K.R. Plasma membrane localization signals in the light chain of botulinum neurotoxin. Proc. Natl. Acad. Sci. USA 2004, 101, 3208–3213. [Google Scholar]
- Ferrer-Montiel, A.V.; Canaves, J.M.; DasGupta, B.R.; Wilson, M.C.; Montal, M. Tyrosine phosphorylation modulates the activity of clostridial neurotoxins. J. Biol. Chem. 1996, 271, 18322–18325. [Google Scholar]
- Ibanez, C.; Blanes-Mira, C.; Fernandez-Ballester, G.; Planells-Cases, R.; Ferrer-Montiel, A. Modulation of botulinum neurotoxin A catalytic domain stability by tyrosine phosphorylation. FEBS Lett. 2004, 578, 121–127. [Google Scholar] [CrossRef]
- Ellis, R.J. Macromolecular crowding: obvious but underappreciated. Trends Biochem. Sci. 2001, 26, 597–604. [Google Scholar]
© 2010 by the authors; licensee MDPI, Basel, Switzerland This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).